This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grima, M. Articles by Imbs, J. L. Search for Related Content PubMed PubMed Citation Articles by Grima, M. Articles by Imbs, J. L.

Hypertension, Vol 17, 492-496, Copyright © 1991 by American Heart Association

ARTICLES

In vitro tissue potencies of converting enzyme inhibitors. Prodrug activation by kidney esterase

M Grima, C Welsch, B Michel, M Barthelmebs and JL Imbs
Institut de Pharmacologie, Universite Louis Pasteur, Strasbourg, France.

The inhibition of angiotensin converting enzyme by ramipril, ramiprilat, enalapril, enalaprilat, and captopril was studied in the plasma and various tissues (lung, heart, renal cortex, renal medulla) of normotensive rats and spontaneously hypertensive rats. Displacement curves for [3H]ramiprilat were established on each tissue with the converting enzyme inhibitors, and their potencies were expressed as the concentration that inhibited 50% of the specific [3H]ramiprilat binding. In the plasma, lung, and heart, the order of activities was: ramiprilat greater than enalaprilat greater than captopril greater than ramipril greater than enalapril. This order was different in the kidney (cortex and medulla): ramiprilat greater than enalaprilat greater than ramipril greater than captopril greater than enalapril. For ramiprilat, enalaprilat, and captopril, there were no differences in their respective potencies between tissues or between rat strains. However, the two prodrugs ramipril and enalapril were 10-30 times more active in the kidney than in the other tissues in both groups of rats. This was due to the deesterification of the prodrugs: in the presence of an esterase inhibitor (diethyl nitrophenyl phosphate, 10 microM), the potencies of ramipril in the kidney were not different from that obtained in the lung, which was not affected by the presence of the esterase inhibitor. These results suggest that the variations in the tissue activities of an angiotensin converting enzyme inhibitor are probably not due to differences in tissue affinities of the angiotensin converting enzyme inhibitor but depend on the concentration of this angiotensin converting enzyme inhibitor in each tissue.

This article has been cited by other articles:

				R. P. Marshall, P. Gohlke, R. C. Chambers, D. C. Howell, S. E. Bottoms, T. Unger, R. J. McAnulty, and G. J. Laurent Angiotensin II and the fibroproliferative response to acute lung injury Am J Physiol Lung Cell Mol Physiol, January 1, 2004; 286(1): L156 - L164. [Abstract] [Full Text] [PDF]

				G. L. Sirianni and K. S. Pang Inhibition of Esterolysis of Enalapril by Paraoxon Increases the Urinary Clearance in Isolated Perfused Rat Kidney Drug Metab. Dispos., August 1, 1999; 27(8): 931 - 936. [Abstract] [Full Text]

				N. K. Hollenberg and E. Guidi ACE Inhibitors and Renal Vascular Responses in the Spontaneously Hypertensive Rat Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 161 - 169. [Abstract] [PDF]